The study shows that the CGM097 based treatment reactivates p53, at therapeutically relevant doses of CGM097, and suggests that highly specific scheduling is required to mitigate the risk of severe thrombocytopenia. The gene discussed is TP53; the disease is Thrombocytopenia.